Preferences Of Patients And Oncologists For The Characteristics Of The Treatment For RCC In Spain And Portugal

Bristol-Myers Squibb1 site in 1 country105 target enrollmentAugust 5, 2019

ConditionsRenal Cell Carcinoma

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Renal Cell Carcinoma
Sponsor: Bristol-Myers Squibb
Enrollment: 105
Locations: 1
Primary Endpoint: Utility: Renal cell carcinoma (RCC) participants' preferences
Status: Completed
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this observational study is to determine patients' and professionals' preferences for the characteristics (attributes) of the treatment for Renal cell carcinoma (RCC) in Spain and Portugal.

Detailed Description

This study uses a literature review, qualitative (focus groups) and quantitative methods (discrete-choice experiment, DCE) to determine renal cell carcinoma (RCC) participants and oncologists' preferences. In this clinical trial, the study team will develop a survey consisting of comparisons of hypothetical treatment profiles (scenarios). Scenarios are presented to participants, and each participant chooses the most preferable.

Registry

clinicaltrials.gov

Start Date

August 5, 2019

End Date

July 13, 2020

Last Updated

4 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Bristol-Myers Squibb

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Oncologists from Spain and Portugal will be identified by the promoter and invited to participate in the study in accordance with the inclusion criteria described below.
•The oncologist is currently working in a Spanish or Portuguese public hospital.
•The oncologist has at least 2 years of experience in the management of participants with Renal Cell Carcinoma (RCC).
•The oncologist has agreed to participate in the study.
•Participants with a diagnosis of RCC will be identified and recruited by the Principal Investigators of the study, taking into account the inclusion criteria described below.
•The participant has been diagnosed with RCC for a minimum of 2 months before study inclusion.
•The participant has received or is currently receiving pharmacological treatment for RCC;
•The participant has provided the informed consent to participate in the study.
•The participant must be able to read, understand and complete the survey instrument according to the judgment of the responsible physician.

Exclusion Criteria

•Not applicable

Outcomes

Primary Outcomes

Utility: Renal cell carcinoma (RCC) participants' preferences

Time Frame: At Baseline

Utility (preference score) derived for a treatment alternative choice (scenario)

Utility: Oncologists' preferences

Time Frame: At Baseline

Utility (preference score) derived for a treatment alternative choice (scenario)

Secondary Outcomes

Distribution of socio-demographic characteristics of Renal cell carcinoma (RCC) participants: Age(At Baseline)
Distribution of clinical characteristics of RCC participants: Time since RCC diagnosis(At Baseline)
Distribution of socio-demographic characteristics of RCC participants: Working situation(At Baseline)
Distribution of socio-demographic characteristics of RCC participants: Other costs derived from the visit to the hospital (parking, meals...)(At Baseline)
Distribution of clinical characteristics of RCC participants: American Joint Committee on Cancer (AJCC) Staging(At Baseline)
Distribution of clinical characteristics of RCC participants: Charlson index(At Baseline)
Distribution of clinical characteristics of RCC participants: Karnofsky Performance Scale Index(At Baseline)
Distribution of clinical characteristics of RCC participants: Identification of previous pharmacological treatments received by the participant for the treatment of RCC(At Baseline)
Distribution of socio-demographic characteristics of oncologists: Gender(At Baseline)
Distribution of socio-demographic characteristics of oncologists: Years of experience in oncology(At Baseline)
Distribution of socio-demographic characteristics of RCC participants: Place of residence(At Baseline)
Distribution of socio-demographic characteristics of RCC participants: Gender(At Baseline)
Distribution of socio-demographic characteristics of RCC participants: Economic status (income)(At Baseline)
Distribution of socio-demographic characteristics of RCC participants: Education level(At Baseline)
Distribution of clinical characteristics of RCC participants: Current drug treatment (if applicable)(At Baseline)
Distribution of socio-demographic characteristics of oncologists: Other types of cancer treated(At Baseline)
Distribution of socio-demographic characteristics of oncologists: Level/ classification of hospital where employed(At Baseline)
Distribution of socio-demographic characteristics of RCC participants: Transport to the hospital: means, duration and cost(At Baseline)
Distribution of clinical characteristics of RCC participants: Description of previous pharmacological treatments received by the participant for the treatment of RCC(At Baseline)
Distribution of socio-demographic characteristics of oncologists: Age(At Baseline)
Distribution of socio-demographic characteristics of oncologists: Province where employed(At Baseline)
Distribution of socio-demographic characteristics of oncologists: Years of experience in RCC(At Baseline)
Distribution of socio-demographic characteristics of oncologists: Number of participants with RCC seen per year(At Baseline)